Literature DB >> 11788979

Opportunity costs and uncertainty in the economic evaluation of health care interventions.

P Sendi1, A Gafni, S Birch.   

Abstract

Considerable methodological research has been conducted on handling uncertainty in cost-effectiveness analysis. The current literature suggests the concepts of net health benefits and cost-effectiveness acceptability curves to circumvent the technical shortcomings of cost-effectiveness ratio statistics. However, these approaches do not provide a solution for the inherent problem that the threshold cost-effectiveness ratio itself is unknown. The authors suggest analysing uncertainty in cost-effectiveness analysis by directly addressing the concept of opportunity costs using the decision rule described by Birch and Gafni (1992) and introduce a new graphical framework (the "decision making plane") for communicating with policy makers. Copyright 2002 John Wiley & Sons, Ltd.

Mesh:

Year:  2002        PMID: 11788979     DOI: 10.1002/hec.641

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  22 in total

1.  Inclusion of drugs in provincial drug benefit programs: Should "reasonable decisions" lead to uncontrolled growth in expenditures?

Authors:  Amiram Gafni; Stephen Birch
Journal:  CMAJ       Date:  2003-04-01       Impact factor: 8.262

2.  NICE methodological guidelines and decision making in the National Health Service in England and Wales.

Authors:  Amiram Gafni; Stephen Birch
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

3.  The HAART side of resource allocation.

Authors:  Pedram Sendi; Amiram Gafni
Journal:  CMAJ       Date:  2003-07-22       Impact factor: 8.262

4.  A risk-adjusted approach to comparing the return on investment in health care programs.

Authors:  Pedram Sendi; Maiwenn J Al; Heinz Zimmermann
Journal:  Int J Health Care Finance Econ       Date:  2004-09

5.  The NICE reference case requirement: more pain for what, if any, gain?

Authors:  Amiram Gafni; Stephen Birch
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

6.  Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: a critical appraisal.

Authors:  Christopher Evans; Manouche Tavakoli; Bruce Crawford
Journal:  Health Care Manag Sci       Date:  2004-02

7.  Future challenges for the economic evaluation of healthcare: patient preferences, risk attitudes and beyond.

Authors:  John F P Bridges
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 8.  Information created to evade reality (ICER): things we should not look to for answers.

Authors:  Stephen Birch; Amiram Gafni
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 9.  Estimation, power and sample size calculations for stochastic cost and effectiveness analysis.

Authors:  S D Walter; Amiram Gafni; Stephen Birch
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

10.  Cost-effectiveness league tables: valuable guidance for decision makers?

Authors:  Josephine Mauskopf; Frans Rutten; Warren Schonfeld
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.